N-terminal pro-brain natriuretic peptide and coronary collateral formation in patients undergoing primary percutaneous coronary intervention

Bo Eun Park1 · Jang Hoon Lee1,2 · Hyeon Jeong Kim1 · Hong Nyun Kim1 · Se Yong Jang1,2 · Myung Hwan Bae1,2 · Dong Heon Yang1,2 · Hun Sik Park1,2 · Yongkeun Cho1,2 · Shung Chull Chae1,2

Received: 21 November 2020 / Accepted: 7 May 2021 / Published online: 28 May 2021
© The Author(s) 2021

Abstract
There is insufficient information on the relationship between the N-terminal pro-brain natriuretic peptide (NT-proBNP) level and collateral circulation (CC) formation after primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction. We analyzed 857 patients who underwent primary PCI. The serum NT-proBNP levels were measured on the day of admission, and the CC was scored according to Rentrop’s classification. Log-transformed NT-proBNP levels were significantly higher in patients with good CC compared to those with poor CC (6.13 ± 2.01 pg/mL versus 5.48 ± 1.97 pg/mL, \( p < 0.001 \)). The optimum cutoff value of log NT-proBNP for predicting CC was 6.04 pg/mL. Log NT-proBNP ≥ 6.04 pg/mL (odds ratio 2.23; 95% confidence interval 1.51–3.30; \( p < 0.001 \)) was an independent predictor of good CC. CC development was higher in patients with a pre-TIMI flow of 0 or 1 than those with a pre-TIMI flow of 2 or 3 (22.6% versus 8.8%, \( p = 0.001 \)). The incidence of left ventricular (LV) dysfunction (< 50%) was greater in patients with a pre-TIMI flow of 0 or 1 (49.8% versus 35.5%, \( p < 0.001 \)). The release of NT-proBNP was greater in patients with LV dysfunction (34.3% versus 15.6%, \( p < 0.001 \)). The incidence of good CC was greater in patients with log NT-proBNP levels ≥ 6.04 pg/ml (16.8% versus 26.2%, \( p = 0.003 \)). The association between NT-proBNP and collateral formation was not influenced by pre-TIMI flow and LV function. NT-proBNP appears to reflect the degree of collateral formation in the early phase of STEMI and might have a new role as a useful surrogate biomarker for collateral formation in patients undergoing primary PCI.

Keywords Collateral circulation · N-terminal pro-B type natriuretic peptide · Acute myocardial infarction · Percutaneous coronary intervention

Introduction
The coronary collateral circulation (CC) is thought to provide blood for the ischemic myocardium and an interconnecting network to alleviate the burden of myocardial ischemia [1–3]. It is well known that well-developed CCs can reduce the size of infarct, preserve ventricular function, improve myocardial remodeling, prevent the formation of left ventricular (LV) aneurysm, resulting in fewer future cardiovascular events and improved rates of survival [4–7].

N-terminal pro-brain natriuretic peptide (NT-proBNP) is secreted from the myocardium due to increased myocardial wall stress [8]. Recently, it has been found that NT-proBNP can act as a stimulator of angiogenesis [9, 10]. However, in patients with ST-segment elevation myocardial infarction (STEMI), there insufficient information on the relationship between NT-proBNP and collateral formation after primary percutaneous coronary intervention (PCI). In the present study, we sought to elucidate the potential mechanism regarding association of the NT-proBNP level with coronary collateral formation in patients with STEMI after primary PCI.
**Materials and methods**

This observational study included 857 consecutive patients who underwent primary PCI after STEMI and were enrolled in the Korean Acute Myocardial Infarction registry (KAMIR). The KAMIR is a Korean, prospective, open, observational, multicenter, online registry of AMI with support of the Korean Society of Cardiology that was initiated in November 2005; details of the KAMIR have been published previously [11]. The study was approved by the Institutional Review Board of Kyungpook National University Hospital (KNUIH 2011-11-023), and all patients provided written informed consent to participate. The study was performed in accordance with the ethical standards outlined in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

The flow diagram of the study is shown in Fig. 1. Between November 2005 and November 2011, 2883 patients with AMI were recruited. Baseline clinical data, including NT-proBNP, were available for 2822 patients; among whom, 1672 who had a non-STEMI, 198 who underwent thrombolysis or conservative treatment, 11 who had no significant stenosis, and 84 without available baseline angiogram were excluded.

AMI was diagnosed based on a characteristic clinical presentation, serial changes on electrocardiogram indicating infarction, and an increase in cardiac enzyme levels [12]. STEMI was defined by new ST elevation in two or more contiguous leads, measuring more than 0.2 mV in leads V1–V3, or 0.1 mV in all other leads. We analyzed the baseline clinical characteristics, angiographic findings, procedural data, and medications before hospitalization. The left ventricular ejection fraction (LVEF) was determined using two-dimensional echocardiography at the index hospitalization. NT-pro-BNP was measured at the time of admission using an electrochemiluminescence immunoassay method (Modular Analytics E170; Roche Diagnostics, Mannheim, Germany).

Coronary CC data were collected at baseline through standard angiography, with six views of the left coronary artery and two views of the right coronary artery and used for the interpretation of collateral vessels. CC was scored according to Rentrop’s classification [13]. A grade of 0 was given for no visible collaterals, 1 for a filled small side branch, 2 for filled major side branches of the main epicardial vessel, and 3 for main epicardial vessels filled by collaterals. Grades 0 and 1 were regarded as poor, and grades 2 and 3 were regarded as good CC. All data were entered into an electronic web-based case report form. The KAMIR protocol was approved by the ethics committee.

Data are shown as mean ± SD for continuous variables, and percentages for categorical variables. Student’s t test was used to perform all comparisons between the baseline variables and the continuous variables, and the Pearson Chi-square test was used to compare the categorical variables. Patients were categorized into two groups according to the presence of coronary CC: poor collateral circulation (n = 693) and good collateral circulation (n = 164). Univariate analyses were performed to determine the predictors for good CC. A logistic regression analysis model was used to compute the odds ratios (ORs) and 95% confidence intervals (CIs) of independent predictors of good collateral circulation. Variables with p values < 0.05 on univariate analysis were entered into the multivariate logistic regression model, namely the presence of preinfarction angina, pre-thrombolysis in MI (TIMI) flow grade of 0 or 1, multivessel disease, left anterior descending artery (LAD) as a culprit vessel, symptom-to-door time > 6 h, and log-transformed NT-proBNP. We estimated the receiver-operating characteristic (ROC) curves and the areas under the ROC curves (AUC) of NT-proBNP to identify the optimum cutoff value in the corresponding logistic models. The serum levels of NT-proBNP were compared within the collateral grade categories 0, 1, and 2/3, and with the analysis of variance according to the symptom-to-door time, presence of preinfarction angina, pre-TIMI flow of 0 or 1, and multivessel disease. For all analyses, a 2-sided p value < 0.05 was considered statistically significant. Statistical analysis was performed using SPSS software (version 18.0; SPSS Inc., Chicago, IL, USA).

**Results**

The mean age of the study population was 63 ± 12 years, and 634 (74.0%) were men. Overall, 429 (50.1%) had angiographic evidence of CC, including 265 (30.9%) with grade 1 and 164 (19.1%) with grade 2 or 3 (Fig. 2). The baseline
characteristics of the study population are shown in Table 1. Patients with good CC had a greater prevalence of preinfarction angina ($p = 0.038$) and symptom-to-door time > 6 h ($p = 0.009$). Log-transformed NT-proBNP levels were significantly higher in patients with good CC compared to those with poor CC (6.13 ± 2.01 pg/mL versus 5.48 ± 1.97 pg/mL, $p < 0.001$). Among the angiographic findings, patients with good CC had a greater prevalence of multivessel disease ($p = 0.022$), pre-TIMI flow grade of 0 or 1 ($p < 0.001$), and a lower prevalence of LAD-related MI ($p < 0.001$) (Table 2). The prevalence of collaterals increased as the quartiles of serum NT-proBNP levels increased, from 13.4% in quartile 1 (< 4.06 pg/mL) to 15.1% in quartile 2 (4.06–5.40 pg/mL), 22.0% in quartile 3 (5.41–7.15 pg/mL), and 26.2% in quartile 4 (< 7.15 pg/mL) ($p$ for trend) (Fig. 3).

![Fig. 2 Distribution of coronary collateral circulation](image)

Table 1 Clinical characteristics of study subjects

| Variables                       | Overall (N=857) | Collateral circulation | p value |
|---------------------------------|-----------------|------------------------|---------|
|                                 | Poor (N=693)    | Good (N=164)           |         |
| Demographics                    |                 |                        |         |
| Age (year-old)                  | 62.8 ± 12.2     | 62.9 ± 11.7            | 62.3 ± 12.9 | 0.585 |
| Male                            | 634 (74.0%)     | 516 (74.5%)            | 118 (72.0%) | 0.510 |
| Body mass index (kg/m²)         | 23.7 ± 3.1      | 23.7 ± 3.2             | 23.6 ± 3.0 | 0.538 |
| Initial presentation            |                 |                        |         |
| Preinfarct angina               | 513 (59.9%)     | 403 (58.2%)            | 110 (67.1%) | 0.038 |
| Killip class > 1                | 222 (25.9%)     | 171 (24.7%)            | 51 (31.1%) | 0.093 |
| Symptom-to-door time > 6-h      | 217 (25.7%)     | 163 (23.8%)            | 54 (33.8%) | 0.009 |
| Left ventricular ejection fraction | 49.6 ± 10.7   | 49.8 ± 10.6            | 48.5 ± 11.5 | 0.161 |
| Past history                    |                 |                        |         |
| Coronary heart disease          | 85 (9.9%)       | 62 (8.9%)              | 23 (14.0%) | 0.050 |
| Hypertension                    | 601 (70.1%)     | 482 (69.6%)            | 119 (72.6%) | 0.449 |
| Diabetes mellitus               | 204 (24.0%)     | 162 (23.5%)            | 42 (25.8%) | 0.550 |
| Hyperlipidemia                  | 188 (22.4%)     | 155 (22.9%)            | 33 (20.4%) | 0.494 |
| Current smoking                 | 419 (48.9%)     | 340 (49.1%)            | 79 (48.2%) | 0.825 |
| Laboratory findings             |                 |                        |         |
| Hemoglobin (g/dL)               | 13.8 ± 1.8      | 13.9 ± 1.8             | 13.8 ± 1.8 | 0.797 |
| Serum uric acid (mg/dL)         | 5.5 ± 1.8       | 5.5 ± 1.8              | 5.2 ± 1.7 | 0.110 |
| eGFR (mL/min)                   | 85.7 ± 26.2     | 84.2 ± 26.3            | 87.5 ± 24.6 | 0.136 |
| Serum peak cTnI (ng/mL)         | 97.3 ± 181.6    | 94.0 ± 165.5           | 81.1 ± 97.5 | 0.335 |
| Total cholesterol (mg/dL)       | 181.4 ± 44.0    | 181.6 ± 44.1           | 182.6 ± 45.7 | 0.805 |
| Log NT-proBNP (pg/mL)           | 5.54 ± 2.14     | 5.48 ± 1.97            | 6.13 ± 2.01 | < 0.001 |
| Medications prior to admission  |                 |                        |         |
| Antiplatelet agent              | 60 (7.9%)       | 45 (7.2%)              | 15 (10.7%) | 0.167 |
| Beta-blockers                   | 33 (4.3%)       | 23 (3.7%)              | 10 (7.2%) | 0.067 |
| ACE-Is/ARBs                     | 48 (6.3%)       | 40 (6.4%)              | 8 (5.8%) | 0.767 |
| Statins                         | 31 (4.1%)       | 22 (3.5%)              | 9 (6.5%) | 0.115 |
| Nitrates                        | 19 (2.9%)       | 14 (2.6%)              | 5 (4.5%) | 0.271 |

Data expressed as mean ± SD or number (percent)

cGFR estimated glomerular filtration rate, cTnI cardiac troponin I, NT-proBNP N-terminal pro-B type natriuretic peptide, ACE-Is angiotensin converting enzyme inhibitors, ARBs angiotensin type II receptor blockers.
In the ROC curve, the AUC of log NT-proBNP for predicting good CC was 0.60 (sensitivity, 54.9% and specificity, 64.8%), and the optimum cutoff value was 6.04 pg/mL (Fig. 4). In the multivariate logistic regression model, log-transformed NT-proBNP ≥ 6.04 pg/mL (OR 2.23; 95% CI 1.51–3.30; \(p < 0.001\)) was an independent predictor of good CC, in addition to a pre-TIMI flow grade of 0 or 1 (OR 2.89; 95% CI 1.71–4.90; \(p < 0.001\)) and LAD-related MI (OR 0.47; 95% CI 0.32–0.68; \(p < 0.001\)) was an independent predictor of good CC after adjusting for confounding variables (Table 3).

The serum levels of NT-proBNP were compared within the CC grade categories 0, 1, and 2/3. The serum levels increased with CC grade (5.36 ± 1.91 pg/mL versus 5.68 ± 2.04 pg/mL versus 6.13 ± 2.01 pg/mL, \(p < 0.001\)) (Fig. 5).

Good CC was greater in patients with a pre-TIMI flow of 0 or 1 (22.6% versus 8.8%, \(p = 0.001\)) (Fig. 6a). LV dysfunction (LVEF < 50%) was greater in patients with a pre-TIMI flow of 0 or 1 (49.8% versus 35.5%, \(p < 0.001\)). High NT-proBNP levels were more common in patients with LV dysfunction (34.3% versus 15.6%, \(p < 0.001\)).

### Table 2

| Variables                        | Overall (N=857) | Collateral circulation | \(p\) value |
|----------------------------------|----------------|------------------------|-------------|
| Coronary artery disease          |                |                        |             |
| Left main, isolated              | 2 (0.2%)       | 1 (0.1%)               | 1 (0.6%)    |
| Left main, complex               | 13 (1.5%)      | 12 (1.7%)              | 1 (0.6%)    |
| 1-vessel disease                 | 552 (64.4%)    | 459 (66.2%)            | 93 (56.7%)  |
| 2-vessel disease                 | 195 (22.8%)    | 152 (21.9%)            | 43 (26.2%)  |
| 3-vessel disease                 | 95 (11.1%)     | 69 (10.0%)             | 26 (15.9%)  |
| Multivessel disease              | 305 (35.6%)    | 234 (33.8%)            | 71 (43.3%)  |
| Infarct related artery           |                |                        |             |
| Left main stem                   | 15 (1.8%)      | 11 (1.6%)              | 4 (2.4%)    |
| Left anterior descending artery  | 417 (48.7%)    | 360 (51.9%)            | 57 (34.8%)  |
| Left circumflex artery           | 82 (9.6%)      | 69 (10.0%)             | 13 (7.9%)   |
| Right coronary artery            | 343 (40.0%)    | 253 (36.5%)            | 90 (54.9%)  |
| Pre-TIMI flow 0/1                | 642 (74.9%)    | 497 (71.7%)            | 145 (88.4%) |
| Post-TIMI flow 3                 | 804 (96.2%)    | 652 (96.3%)            | 152 (95.6%) |
| Drug-eluting stent               | 568 (66.3%)    | 452 (65.2%)            | 116 (70.7%) |

Data expressed as mean ± SD or number (percent)

**TIMI** thrombolysis in myocardial infarction

**Fig. 3** Prevalence of collateral circulation to the infarct-related artery based on a quartile of the serum N-terminal pro-B type natriuretic peptide levels

**Fig. 4** Receiver-operating characteristics analysis of N-terminal pro-B type natriuretic peptide for good collateral circulation. AUC area under the curve, CI confidence interval

**Log NT-proBNP = 6.04 pg/mL**

of NT-proBNP increased with CC grade (5.36 ± 1.91 pg/mL versus 5.68 ± 2.04 pg/mL versus 6.13 ± 2.01 pg/mL, \(p < 0.001\)) (Fig. 5).
Good CC was greater in patients with high NT-proBNP levels (16.8% versus 26.2%, \( p = 0.003 \)).

There was no significant difference in patients with a pre-TIMI flow of 0 or 1 between those with log NT-proBNP levels \( \geq 6.04 \text{ pg/ml} \) and those with log NT-proBNP levels \( < 6.04 \text{ pg/ml} \) (25.2% versus 24.2%, \( p = 0.759 \)) (Fig. 6b). High NT-proBNP was significantly greater in patients with LV dysfunction regardless of pre-TIMI flow.

There was no significant difference between patients with good CC among those with and without LV dysfunction (19.8% versus 18.7%, \( p = 0.695 \)) (Fig. 6c). Good CC was significantly greater in patients with high NT-proBNP levels regardless of LV function.

### Discussion

The principle findings of this study were as follows. First, an elevated level NT-proBNP was associated with collateral development in patients undergoing primary PCI after STEMI. Second, an elevated level of serum NT-proBNP was an independent predictor of good CC. Third, a pre-TIMI flow of 0 or 1 was associated with good CC, but it was not associated with NT-proBNP. Fourth, LV function was associated with NT-proBNP but not with good CC. Therefore, the relationship between NT-proBNP and CC was not influenced by pre-TIMI flow and LV function.

To the best of our knowledge, this is the first study to demonstrate the association between NT-proBNP and the formation of collateral arteries in patients who underwent primary PCI after STEMI. Previous studies have shown that the extent of collateral circulation is affected by age, sex, presence of pre-TIMI flow grade of 0 or 1, anterior wall AMI, multivessel disease, preinfarction angina, and time from symptom onset to cardiac catheterization [14–17]. A recent study demonstrated the association between BNP level and the development of CC in chronic stable angina [18]. Our study adds novel insight to the previous finding that the NT-proBNP level is related to the development of CC, even after adjusting confounding variables and is an independent predictor of collateral formation in STEMI.

Several studies have demonstrated that BNP is overexpressed in the ischemic myocardium [19, 20]. The time course of the plasma level of BNP in patients with AMI can be divided into monophasic and biphasic patterns [21]. The plasma levels and the presence or absence of the second peak of plasma BNP in the subacute phase appear to reflect the degree of LV dysfunction and infarct size. However, an early increase within 4–8 h after the onset of symptoms is not solely related to the degree of LV dysfunction and infarct size. In the present study, the serum NT-proBNP levels were significantly higher in patients with good CC. However, there was no significant difference in LVEF between patients with and without good CC. This suggests that an early increase of NT-proBNP within 4–8 h after the onset of symptoms is associated with collateral formation. BNP in the early phase of AMI is one of the acute-phase reactants that are released in response to myocardial necrosis, local mechanical stress, or both on ventricular myocytes, even when global hemodynamic parameters are within the normal range [21, 22].

Although we found that the circulating NT-proBNP levels in early phase of AMI correlated with the degree of collateral formation, the causative mechanisms remain unclear. In patients with STEMI, myocardial ischemia is a potent trigger for collateral formation, and the severity of
(a)

Total occlusion

LV dysfunction

NT-proBNP ↑

Collateral circulation ↑

(b)

Total occlusion

LV dysfunction

NT-proBNP ↑

Patients with high NT-proBNP

Collateral circulation ↑
myocardial ischemia is positively correlated with collateral formation. In the present study, CC development was more common in patients with a pre-TIMI flow of 0 or 1 than those with a pre-TIMI flow of 2 or 3. Therefore, we hypothesized that total occlusion in STEMI results in LV dysfunction, which causes myocardial wall stress, and that NT-proBNP is released from the ventricular myocardium. This increase in NT-proBNP could lead to the development of CC. The results of our study support our hypothesis as follows. LV dysfunction was significantly more prevalent in patients with a pre-TIMI flow of 0 or 1. NT-proBNP was released more in patients with LV dysfunction. Finally, this release of NT-proBNP was associated with the development of CC. Interestingly, the release of NT-proBNP was not associated with pre-TIMI flow, but it was associated with LV dysfunction. Moreover, LV dysfunction was not associated with the development of CC, but it was associated with the release of NT-proBNP. As a result, the circulating NT-proBNP level in the early phase of AMI is independently associated with collateral formation.

Although we hypothesized that an increase of NT-proBNP could lead to the development of CC, it is uncertain whether this association is causal or a mere epiphenomenon. Recent animal studies revealed that BNP is a strong stimulator for angiogenesis in ischemic conditions. A previous study reported that transgenic mice overexpressing BNP showed improved reendothelialization after induced ischemia [23]. Recently, BNP has been reported to act as a potent vasculogenic agent by enhancing the number, proliferation, adhesion, and migration of endothelial progenitor cells through paracrine activation of the receptor guanylyl cyclase-A [9, 10]. This suggests that BNP plays a central role in endothelial homeostasis and acts as a regulator of vascular tone and endothelial regeneration [24–27]. The results of our study are consistent with those of previous animal studies that showed that the CC grade increases as the serum level of NT-proBNP rises. Therefore, we assumed that NT-proBNP

![Fig. 6](image_url)

**Fig. 6** a Plausible mechanism of the development collateral circulation. Left, relationship between pre-TIMI flow and collateral circulation. Right upper, relationship between pre-TIMI flow and LV dysfunction and log NT-proBNP. Right lower, relationship between log NT-proBNP and collateral circulation. b Plausible mechanism of the development collateral circulation. Left, relationship between pre-TIMI flow and log NT-proBNP. Right, relationship between LV dysfunction and NT-proBNP, regardless of pre-TIMI flow. CC: collateral circulation, LVEF: left ventricular ejection fraction. c Plausible mechanism of the development collateral circulation. Left, relationship between LVEF and collateral circulation. Right, relationship between log NT-proBNP and collateral circulation regardless of LV dysfunction. CC collateral circulation, LVEF left ventricular ejection fraction.
has provasculogenic properties to promote collateral formation in post-MI patients. Although there is no management strategy based on early elevated BNP levels for patients with STEMI at this time, NT-proBNP could be useful for monitoring the effectiveness of angiogenic therapy and identifying individuals in need of such treatment in the near future.

In the present study, we hypothesized that serum NT-proBNP levels would be elevated for angiogenesis in the acute stage in patients with STEMI because of severe myocardial ischemia. Accordingly, CC develops as the serum NT-proBNP level rises. In the conventional concept, good CC may preserve LVEF leading to low BNP (Supplementary Fig. 1A). However, BNP is also strongly correlated with the severity of myocardial ischemia, and an elevated level of BNP is, therefore, positively associated with good CC (Supplementary Fig. 1B). Therefore, in the novel concept, BNP is a strong stimulator for angiogenesis reflecting myocardial ischemia, and as a result, good CC would be developed immediately after STEMI.

Our research has several limitations that should be considered. First, because this was an observational study, we cannot completely exclude the possibility of residual confounding factors, although we attempted to control for selection bias with multivariate statistical methods. Therefore, our results should only be regarded as hypothesis generating. Second, we assessed coronary collateralization by Rentrop’s score instead of the collateral flow index. However, Rentrop’s score was used extensively in previous studies investigating the collateral development in humans and was shown to be a well-documented and reproducible method to assess coronary collateral vessels. Therefore, these limitations should not undermine the strength of this study.

In conclusion, the serum level of NT-proBNP was increased markedly in patients with good CC. Although the precise mechanisms by which NT-proBNP is synthesized and released remain to be elucidated, the serum level of NT-proBNP appears to reflect the degree of collateral formation in the early phase of AMI.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00380-021-01866-3.

Funding This research was supported by a fund (2013-E63005-02) from the Korea Centers for Disease Control and Prevention.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959–969

13. Rentrop KP, Cohen M, Blanke H, Phillips RA (1985) Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 5:587–592

14. Kurotobi T, Sato H, Kinjo K, Nakatani D, Mizuno H, Shimizu M, Imai K, Hirayama A, Kodama K, Hori M, OACIS Group (2004) Reduced collateral circulation to the infarct-related artery in elderly patients with acute myocardial infarction. J Am Coll Cardiol 44:28–34

15. Antoniucci D, Valenti R, Moschi G, Migliorini A, Trapani M, Santoro GM, Bolognese L, Cerisano G, Buonamici P, Dovallini EV (2002) Relation between preintervention angiographic evidence of coronary collateral circulation and clinical and angiographic outcomes after primary angioplasty or stenting for acute myocardial infarction. Am J Cardiol 89:121–125

16. Vyssoulis G, Kyriakidis M, Karpanou E, Kyriakidis C, Sfikakis P, Barbetseas J, Toutouzas P (1990) A prospective angiographic study of the coronary collateral circulation in coronary arterial disease. Int J Cardiol 27:187–191

17. Rentrop KP, Feit F, Sherman W, Thornton JC (1989) Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction: report from the second Mount Sinai-New York University reperfusion trial. Circulation 80:1166–1175

18. Xi W, Cheng G, Lv S, Gao Q, Bu G, Zhou Y, Xu G (2011) An elevated level of BNP in plasma is related to the development of good collateral circulation in coronary artery disease. Eur J Cardiovasc Prev Rehabil 18:797–802

19. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB (2003) Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 17:1105–1107

20. Luo Y, Jiang C, Belanger AJ, Akita GY, Wadsworth SC, Gregory RJ, Vincent KA (2006) A constitutively active hypoxia-inducible factor-1alpha/VP16 hybrid factor activates expression of the human B-type natriuretic peptide gene. Mol Pharmacol 69:1953–1962

21. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K (1993) Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82–91

22. Kushner I (1982) The phenomenon of the acute phase response. Ann NY Acad Sci 389:39–48

23. Yamahara K, Itoh H, Chun TH, Ogawa Y, Yamashita J, Sawada N, Fukunaga Y, Sone M, Yurugi-Kobayashi T, Miyashita K, Tsubimoto H, Kook H, Feil R, Garbers DL, Hofmann F, Nakao K (2003) Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci USA 100:3404–3409

24. Ueno H, Haruno A, Morisaki N, Furuya M, Kangawa K, Takeshita A, Saito Y (1997) Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 96:2272–2279

25. Zhao L, Long L, Morrell NW, Wilkins MR (1999) NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 99:605–607

26. Doi K, Ikeda T, Itoh H, Ueyama K, Hosoda K, Ogawa Y, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Fukunaga Y, Saito T, Sone M, Yamahara K, Kook H, Komeda M, Ueda M, Nakao K (2001) C-type natriuretic peptide induces redifferentiation of vascular smooth muscle cells with accelerated reendothelialization. Arterioscler Thromb Vasc Biol 21:930–936

27. Ohno N, Itoh H, Ikeda T, Ueyama K, Yamahara K, Doi K, Yamashita J, Inoue M, Masatsugu K, Sawada N, Fukunaga Y, Saito T, Komeda M, Ueda M, Nakao K (2002) Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 105:1623–1626

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.